Announcement on Expected Increase in Semi-annual Performance for 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Expected Increase in Semi-annual Performance for 2026
Filed with SSE · · 3 pages · Chinese
Release
Harbin Pharmaceutical Group Co., Ltd. on 6ix
Earlier from Harbin Pharmaceutical
- Announcement on Pledge of Partial Shares of Controlling Shareholder
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Progress in Technology Transfer (Entrustment) Contract Signed by a Wholly-owned Subsidiary and Entry of Daprodustat Tablets into Phase III Clinical Trial (Confirmatory Clinical Study)
- Notice on Convening the 2025 Annual General Meeting
- Announcement on Attending the Online Collective Reception Day for Investors of Listed Companies in Heilongjiang Jurisdiction in 2026 and the 2025 Annual and Q1 2026 Performance Briefing
Later from Harbin Pharmaceutical
- Announcement on Adjustment to the Company's Products in the National Essential Medicines List
- Announcement on Resolutions of the 27th Meeting of the 10th Board of Directors
- Announcement on Severe Abnormal Fluctuations in Stock Trading and Risk Warning
- Announcement on the Affiliated Enterprise's Receipt of the Approval Notice for the Marketing Application of a Chemical API
- Announcement on the Proposed Selection in the 12th Batch of National Centralized Drug Procurement
Follow Harbin Pharmaceutical into a list and get an email when it puts out news.
Follow Harbin Pharmaceutical